Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New factors controlling bone remodeling.

P Marie1, F Debiais, M Cohen-Solal

  • 1INSERM U349, Viggo Petersen Center, Lariboisière Teaching Hospital, Paris, France.

Joint Bone Spine
|June 30, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient perceptions of osteoporosis management: a qualitative pilot study by a patient advisory group.

Archives of osteoporosis·2025
Same author

Inhibition of sphingosine 1-phosphate protects mice against chondrocyte catabolism and osteoarthritis.

Osteoarthritis and cartilage·2021
Same author

The Matrilin-3 T298M mutation predisposes for post-traumatic osteoarthritis in a knock-in mouse model.

Osteoarthritis and cartilage·2020
Same author

Identification of TGFβ signatures in six murine models mimicking different osteoarthritis clinical phenotypes.

Osteoarthritis and cartilage·2020
Same author

Microcracks in subchondral bone plate is linked to less cartilage damage.

Bone·2019
Same author

Vertebral fractures cascade: potential causes and risk factors.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2018
Same journal

Greater trochanteric bursal distension with intra-bursal rice bodies: an unusual MRI presentation.

Joint bone spine·2026
Same journal

Evaluating the Impact of a Rheumatologist-led Comorbidity Review in Patients with Inflammatory Arthritis.

Joint bone spine·2026
Same journal

What cumulative glucocorticoid dose should trigger sparing strategies in polymyalgia rheumatica?

Joint bone spine·2026
Same journal

Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update.

Joint bone spine·2026
Same journal

Multimodal imaging evaluation of the entheses in spondyloarthritis.

Joint bone spine·2026
Same journal

Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update. What's new?

Joint bone spine·2026
See all related articles

New discoveries in bone cell differentiation include Osf2/Cbfa1 for osteoblast formation and osteoclast differentiating factor (ODF) for osteoclast development. These factors, along with osteoprotegerin, offer potential therapeutic targets for bone disorders like osteoporosis.

Area of Science:

  • Bone biology
  • Cell differentiation
  • Immunology

Background:

  • Mesenchymal stem cell differentiation into osteoblasts is regulated by factors like Osf2/Cbfa1.
  • Osteoclast differentiation is controlled by osteoclast differentiating factor (ODF), a TNF family member.
  • Lymphocytes, particularly T lymphocytes, are implicated in bone loss during inflammation.

Purpose of the Study:

  • To highlight recent discoveries in bone cell differentiation.
  • To discuss the role of key factors in osteoblast and osteoclast formation.
  • To explore the implications of these findings for bone disease treatment.

Main Methods:

  • Review of recent scientific literature on bone cell differentiation.
  • Identification of key regulatory factors such as Osf2/Cbfa1 and ODF.

Related Experiment Videos

  • Analysis of the role of soluble factors and lymphocytes in bone remodeling.

    • Main Results:

    • Osf2/Cbfa1 is crucial for osteoblast differentiation from mesenchymal stem cells.
    • Osteoclast differentiating factor (ODF) is essential for osteoclast differentiation and is inhibited by osteoprotegerin.
    • Activated T lymphocytes produce ODF, linking inflammation to bone loss; B lymphocytes are implicated in estrogen deprivation-related bone loss.

    Conclusions:

    • Osf2/Cbfa1 and ODF are critical targets for osteoporosis treatment.
    • Osteoprotegerin shows promise as an anti-osteoclast agent for bone disorder therapy.
    • Understanding these pathways offers new therapeutic strategies for bone diseases.